Mizutani Yoichi, Nakamura Terukazu, Nomoto Takeshi, Kawauchi Akihiro, Miki Tsuneharu
Dept. of Urology, Kyoto Prefectural University of Medicine.
Gan To Kagaku Ryoho. 2006 Feb;33(2):183-7. doi: 10.2217/14750708.3.2.183.
Approximately 80% of patients with metastatic testicular tumors are cured by cisplatin-containing chemotherapy and surgery. However, the remaining 20% of patients with advanced testicular tumors can not be cured at present. Thus, therapy for these testicular tumors infractory to treatment is the most important issue. Recently, chemotherapy for such tumors is developing, especially salvage chemotherapy using novel anticancer agents(paclitaxel, gemcitabine,irinotecan, docetaxel, oxaliplatin, etc) and high-dose anticancer drugs. Some of the new modalities are very attractive. In this article, we reviewed mainly these new forms of chemotherapy for testicular tumors.
大约80%的转移性睾丸肿瘤患者可通过含顺铂的化疗和手术治愈。然而,其余20%的晚期睾丸肿瘤患者目前无法治愈。因此,治疗这些难治性睾丸肿瘤是最重要的问题。近年来,此类肿瘤的化疗不断发展,尤其是使用新型抗癌药物(紫杉醇、吉西他滨、伊立替康、多西他赛、奥沙利铂等)和高剂量抗癌药物的挽救性化疗。一些新的治疗方式非常有吸引力。在本文中,我们主要综述了这些针对睾丸肿瘤的新型化疗方式。